MUC4 and neoplasm: In the MUC4-overexpressing trastuzumab resistant JIMT1 tumors, tumor metabolic changes were observed exclusively in the treatment arm combining trastuzumab and NAC with a significantly lower %ΔSUVmax (NT = 12.6 ± 7.8 % vs CT = 78.6 ± 10.6, NS = 62.1 ± 12.1 and CS = 75.1 ± 15.5; all p < 0.01) (Figure 4B).